The main overhang in question for the meeting November 15th
The biggest question Dynavax will face on November 15th will be the Wegener's case from clinical trials. Dynavax has done all due dilligence with additional trials and data to properly address this issue with supporting data, analysts at William Blair and Cowen & Company both have reports that properly address that specific case in detail.
Can't remember where (probably posted it to this board a LONG time ago), but I recall reading there was essentially an argument the German doc under whom the case occurred. Might've been a DVAX stmt, come to think of it, because it argued in terms of time between innoculation shots and onset of Wegeners that this should have been classified a random occurrence, versus having a *potential* link to the vaccine. I found the random argument convincing, but not being a subject matter expert, that's worth a grain of salt.